Edward C. Smith

University of Minnesota — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

36h-index5.2kcitations314works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Muscle Physiology and Disorders(42), Aeroelasticity and Vibration Control(37), Vibration Control and Rheological Fluids(28), Neurogenetic and Muscular Disorders Research(23), Composite Structure Analysis and Optimization(22)

Publications296 total

Use cases for pan-sarbecovirus vaccines: a workshop report
Vaccine·2026Open Access
Tension-Tension Fatigue Behavior of Carbon/Epoxy Composites with Carbon Nanotube Interlayers
2026
A Divergent Asymmetric Total Synthesis of Coprophilin and Four Trichodermic Acids via a [1,5]-Hydride Shift–Aldol Cascade
Journal of the American Chemical Society·2025Open Access
Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children
Steroids·2025Open Access
Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients.
Scientific Reports·2025· 1 citedOpen Access
Del-Zota Produced Statistically Significant Increases in Exon Skipping and Dystrophin Levels in EXPLORE44: A Phase 1/2 Study in Patients with DMD44
Neuropediatrics·2025
674PDelpacibart zotadirsen (del-zota) increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44
Neuromuscular Disorders·2025
Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial
Molecular Therapy·2025· 7 citedOpen Access
Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy
Molecular Therapy·2025· 8 citedOpen Access
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial
Nature Medicine·2025· 13 citedOpen Access
HAIP therapy with antibody-drug conjugate delivery of IL-12: early results from a phase II study
HPB·2025
Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years
The Journal of Physiology·2024· 5 citedOpen Access
Flying in helicopters is safer than you might think – an aerospace engineer explains the technology and training that make it so
2024Open Access
Age-Related Blood Levels of Creatine Kinase-MM in Newborns and Patients with Duchenne Muscular Dystrophy: Considerations for the Development of Newborn Screening Algorithms
International Journal of Neonatal Screening·2024· 2 citedOpen Access
The implementation of a walking aid clinic to reduce waiting times for patients referred to community therapy
Physiotherapy·2024
The severity of MUSK pathogenic variants is predicted by the protein domain they disrupt
Human Genetics and Genomics Advances·2024· 1 citedOpen Access
Active Vibration Damping Using Rotor Torque Control in Electric Aircraft
Journal of Guidance Control and Dynamics·2024· 2 cited
Loss of the endoplasmic reticulum protein Tmem208 affects cell polarity, development, and viability
Proceedings of the National Academy of Sciences·2024· 6 citedOpen Access
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy
Neurology·2024· 54 citedOpen Access
Reductions in Functional Muscle Mass Measured Using D3creatine Dilution and Ability to Ambulate in Duchenne Muscular Dystrophy from Ages 4 – 24 Years
SSRN Electronic Journal·2024Open Access
page 1 of 15Next →

Frequent Co-authors

Craig M. McDonald(12), Richard S. Finkel(10), Jean K. Mah(10), Nancy L. Kuntz(9), Paula R. Clemens(9), Eric P. Hoffman(9), Heidi Cope(9), Vandana Shashi(8), Kelly Schoch(8), David B. Goldstein(8), Rebecca C. Spillmann(8), Jill A. Rosenfeld(8), Anne M. Connolly(7), Michael F. Wangler(7), Lisa Emrick(7), Michela Guglieri(7), Diana Castro(7), Allyn McConkie‐Rosell(7), Vamshi K. Rao(6), Brendan Lee(6)